AV Therapeutics is developing Capridine-β, a novel chemotherapy for prostate cancer patients throughout multiple stages and clinical states of treatment. Capridine-β has advantages over existing therapies such as limited side effects, activity against hormone dependent and independent prostate cancer, and effectiveness against taxane resistant prostate cancer. AV Therapeutics is preparing to commence Phase I and II clinical trials of Capridine-β after completing preclinical studies and formulation development. The company is seeking $3 million to fund the planned clinical trials and further development opportunities for Capridine-β and a peptide vaccine to treat prostate cancer.
Breast Cancer - Molecular Basis of HER2+ DiseaseFaryn
This presentation was part of a graduate level advanced molecular cell biology course. It reviews Breast Cancer epidemiology, signs 7 symptoms, diagnosis, genetic testing, hormonal testing and treatment options (briefly), then discusses the specifics of HER2+ cases at the cellular level. It shows how Herceptin and Tykerb work in the cell to block signal cascades, etc.
Pathways and targets how might these affect my treatment decisions gail eckh...Fight Colorectal Cancer
Dr. Gail Eckhardt
Professor and Head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center.
Join us for an exciting webinar about pathways and targets. Dr. Eckhardt will discuss the basic of pathways within a cancer cell, and how (and why) they can affect treatment options for patients. She'll explain how we learn about how new pathways are discovered, and how this information tell us what drugs may work in certain patients and why some drugs don’t.
Dr. Eckhardt will discuss the idea of targeted therapies, and the difference between them and regular chemotherapy. She'll talk about the relationship between pathways and targeted drugs, and how this may impact drug development in the future.
Two new drugs for colorectal cancer may offer new hope for late stage patients, and they might hit the market in 2013.
Dr. Rich Goldberg, physician-in-chief of the Ohio State University Medical Center and a leader in colorectal cancer research is going to give you the straight facts about these drugs:
* What hope might they offer?
* What side effects do they cause?
* Will either be the right drug for you?
About Dr. Goldberg:
Dr. Richard Goldberg is an internationally renowned gastrointestinal oncologist and the physician-in-chief at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Institute (OSUCCC-James). He is a member and former chair of the National Cancer Institute Colorectal Task Force and an international leader in evaluating new agents for the treatment of colorectal cancer and researching inherited colorectal cancer syndromes
Breast Cancer - Molecular Basis of HER2+ DiseaseFaryn
This presentation was part of a graduate level advanced molecular cell biology course. It reviews Breast Cancer epidemiology, signs 7 symptoms, diagnosis, genetic testing, hormonal testing and treatment options (briefly), then discusses the specifics of HER2+ cases at the cellular level. It shows how Herceptin and Tykerb work in the cell to block signal cascades, etc.
Pathways and targets how might these affect my treatment decisions gail eckh...Fight Colorectal Cancer
Dr. Gail Eckhardt
Professor and Head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center.
Join us for an exciting webinar about pathways and targets. Dr. Eckhardt will discuss the basic of pathways within a cancer cell, and how (and why) they can affect treatment options for patients. She'll explain how we learn about how new pathways are discovered, and how this information tell us what drugs may work in certain patients and why some drugs don’t.
Dr. Eckhardt will discuss the idea of targeted therapies, and the difference between them and regular chemotherapy. She'll talk about the relationship between pathways and targeted drugs, and how this may impact drug development in the future.
Two new drugs for colorectal cancer may offer new hope for late stage patients, and they might hit the market in 2013.
Dr. Rich Goldberg, physician-in-chief of the Ohio State University Medical Center and a leader in colorectal cancer research is going to give you the straight facts about these drugs:
* What hope might they offer?
* What side effects do they cause?
* Will either be the right drug for you?
About Dr. Goldberg:
Dr. Richard Goldberg is an internationally renowned gastrointestinal oncologist and the physician-in-chief at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Institute (OSUCCC-James). He is a member and former chair of the National Cancer Institute Colorectal Task Force and an international leader in evaluating new agents for the treatment of colorectal cancer and researching inherited colorectal cancer syndromes
Suresh S. Ramalingam, MD, FACP, FASCO, Alexander Drilon, MD, and John Heymach, MD, PhD, prepared useful Practice Aids pertaining to lung cancer for this CME/MOC activity titled "Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care." For the full presentation, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2IIiRzP. CME/MOC credit will be available until November 29, 2021.
Maria Arcila, MD, Zofia Piotrowska, MD, and Joshua Bauml, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC activity titled “New Horizons in EGFR-Mutated NSCLC: Broadening the Impact of Precision Testing in the Context of an Expanding Treatment Landscape.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC information, and to apply for credit, please visit us at https://bit.ly/3kH1ygr. CME/MOC/CC credit will be available until January 25, 2022.
Join Fight CRC in a webinar about biomarkers. In this session, Dr. Chris Lieu will focus the discussion on the NTRK biomarker, in addition to ctDNA, and Next-Generation Sequencing.
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoMauricio Lema
Ponencia en el VII Congreso internacional de coloproctología, Bogotá, 18.08.2016. Con énfasis en los estudios recientes en terapia antiangiogénica, y el impacto del lado del primario en el pronóstico (y aspectos predictivos) de la enfermedad metastásica.
Suresh S. Ramalingam, MD, FACP, FASCO, Alexander Drilon, MD, and John Heymach, MD, PhD, prepared useful Practice Aids pertaining to lung cancer for this CME/MOC activity titled "Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care." For the full presentation, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2IIiRzP. CME/MOC credit will be available until November 29, 2021.
Maria Arcila, MD, Zofia Piotrowska, MD, and Joshua Bauml, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC activity titled “New Horizons in EGFR-Mutated NSCLC: Broadening the Impact of Precision Testing in the Context of an Expanding Treatment Landscape.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC information, and to apply for credit, please visit us at https://bit.ly/3kH1ygr. CME/MOC/CC credit will be available until January 25, 2022.
Join Fight CRC in a webinar about biomarkers. In this session, Dr. Chris Lieu will focus the discussion on the NTRK biomarker, in addition to ctDNA, and Next-Generation Sequencing.
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoMauricio Lema
Ponencia en el VII Congreso internacional de coloproctología, Bogotá, 18.08.2016. Con énfasis en los estudios recientes en terapia antiangiogénica, y el impacto del lado del primario en el pronóstico (y aspectos predictivos) de la enfermedad metastásica.
Roundtable Expert Discussions on CML Clinical Debates: A Collaborative Video Viewpoint Series With Medscape
This video viewpoint in its original and unaltered format is for educational purposes and is current as of May 31, 2012. All materials contained herein reflect the views of the faculty, and not those of IMER, the CME provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at the user’s own risk, and all users should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
Dócola is a social good organization with the only free care communication platform that consolidates thousands of free and low-cost patient education resources from the leading nonprofit, government, and commercial organizations in one marketplace. Plus, you can easily create and upload your own resources.
INNO HOLDINGS INC. is an innovative building-technology company with a mission to transform the construction industry with our proprietary cold-formed steel- framing technology and other building innovations
Everything Blockchain builds platforms of trust for the modern enterprise and is on a mission to ensure every organization has access to the tools and platforms that enable them to manage, store, and protect data without the cost and complexity that holds them back today. The Company’s patented advances in engineering deliver the essential elements needed for real-world business use: speed, security, and efficiency. Everything Blockchain’s current business lines include: EB Advise, Build DB and EB Control.
ASP Isotope is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Digital Ally, Inc. is a diversified holding company with operations in video solution technology, human and animal health protection products, healthcare revenue cycle management, ticket brokering and marketing, and event production. The Company pursues an acquisition strategy that targets organizations with positive earnings, strong growth potential, innovation, and operational synergies. To maximize long-term shareholder value, Digital Ally intends to spin-off its ticketing and entertainment business lines into a separate public company in 2023. The spin-off will create two optimized, tech-driven public companies with strong growth opportunities and operating metrics.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
Aditxt is a global innovation company focused on discovering and developing precision medicine innovations and deploying them into high-performing businesses. Aditxt’s diverse innovation portfolio includes: Adimune™, Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir™, Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta™, Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at its CLIA certified and CAP accredited clinical laboratory based in Richmond, VA.
1847 Holdings LLC, a publicly traded diversified acquisition holding company, was founded by Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue and Principal of Lazard Freres Strategic Realty Investors. EFSH's investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises and lower-middle market businesses with limited exit options, despite the intrinsic value of their business. Given this dynamic, EFSH can consistently acquire "solid" businesses for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems to improve operations. These improvements may lead to a sale or IPO of an operating subsidiary at considerably higher valuations than the purchase price (as successfully demonstrated with the mid-2020 IPO of 1847 Goedeker on the NYSE American) and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to EFSH's ability to pay regular and special dividends to shareholders.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
SPI Energy is a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions that was founded in 2006 in Roseville, California and is headquartered in McClellan Park, California. The Company has three core divisions: SolarJuice which has solar wholesale distribution, as well as residential solar and roofing installation and solar module manufacturing (Solar4America & SEM Wafertech), SPI Solar and Orange Power which operates a commercial & utility solar division, and the EdisonFuture/Phoenix Motor EV division. SolarJuice is the leader in renewable energy system solutions for residential and small commercial markets and has extensive operations in the Asia Pacific and North America markets. The SPI Solar commercial & utility solar division provides a full spectrum of EPC services to third party project developers, and develops, owns and operates solar projects that sell electricity to the grid in multiple regions, including the U.S., U.K., and Europe. Phoenix Motor is a leader in medium-duty commercial electric vehicles, and is developing EV charger solutions, electric pickup trucks, electric forklifts, and other EV products. SPI maintains global operations in North America, Australia, Asia and Europe and is also targeting strategic investment opportunities in fast growing green energy industries such as battery storage, charging stations, and other EVs which leverage the Company's expertise and substantial solar cash flow.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Boudoir photography, a genre that captures intimate and sensual images of individuals, has experienced significant transformation over the years, particularly in New York City (NYC). Known for its diversity and vibrant arts scene, NYC has been a hub for the evolution of various art forms, including boudoir photography. This article delves into the historical background, cultural significance, technological advancements, and the contemporary landscape of boudoir photography in NYC.
Fashionista Chic Couture Maze & Coloring Adventures is a coloring and activity book filled with many maze games and coloring activities designed to delight and engage young fashion enthusiasts. Each page offers a unique blend of fashion-themed mazes and stylish illustrations to color, inspiring creativity and problem-solving skills in children.
This tutorial offers a step-by-step guide on how to effectively use Pinterest. It covers the basics such as account creation and navigation, as well as advanced techniques including creating eye-catching pins and optimizing your profile. The tutorial also explores collaboration and networking on the platform. With visual illustrations and clear instructions, this tutorial will equip you with the skills to navigate Pinterest confidently and achieve your goals.
This document announces the winners of the 2024 Youth Poster Contest organized by MATFORCE. It lists the grand prize and age category winners for grades K-6, 7-12, and individual age groups from 5 years old to 18 years old.
2. Safe Harbor Statement
This presentation has been prepared for informational purposes only and does not constitute an offer or solicitation to buy securities in AV Therapeutics. (the “Company”
and its subsidiaries including but not limited to AV Therapeutics, Inc.) Any such offer or solicitation will be made only by means of separate investment materials. None of
the information or analyses presented are intended to form the basis for any investment decision, and no specific recommendations are intended. Accordingly, this
presentation does not constitute investment advice or counsel or solicitation for investment in any security.
The Company expressly disclaims any and all responsibility for any direct or consequential loss or damage of any kind whatsoever arising directly or indirectly from: (i) the
use of this document, (ii) reliance on any information contained herein, (iii) any error, omission or inaccuracy in any such information or (iv) any action resulting there from
Certain statements contained herein are "forward-looking statements". Forward-looking statements are identified by such words and phrases as "we expect," "expected
to," "estimates," "estimated," "current outlook," "we look forward to," "would equate to," "projects," "projections," "projected to be," "anticipates," "anticipated," "we believe,"
"could be," and other similar phrases. All statements addressing operating performance, events, or developments that are expected or anticipated to occur in the future,
including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements. Because they are forward
looking, there can be no assurance that they will actually occur and actual results may differ materially from anticipated results.
The information provided in this document is based upon the facts and circumstances known at this time. The Company undertakes no obligation to update these forward-
looking statements after the date of this presentation.
2
3. 2011
~82 M
Range US0.20- 0.04
US $16-4 million
76,055
December 31st
New York
SRFF, New York
Marcum New York
Capital Market Snapshot
Year Incorporated:
Shares Outstanding:
Price (1/2/15):
Market Capitalization:
Average Volume:
December 31st:
Offices:
Legal:
Auditor:
3
4. M.D. Abraham Mittelman and Dr. Raj Tiwari
20-Year Partnership in Cancer Research and Science
4
Drs. Mittelman and Tiwari’s collaboration in cancer research dates back to 1996, both
being trained at Memorial Sloan Kettering Cancer Center, having a combined over 60
years of research experience and 300 research articles in cancer chemotherapy and
immunotherapies. They discovered the use of capridine as a unique chemotherapeutic
agent for PCa
• Capridine unlike other DNA intercalating agent shows PCa specificity, an observation
mirrored by NCI data on its predecessor compound and one that that is not common
for a chemotherapeutic agent
• Active against both hormone dependent and refractory PCa suggesting multiple
cellular targets
• Very low bone marrow toxicities unlike any prevalent chemotherapeutic agent
suggesting targeted activity
• Fulfils an unmet clinical need as Pca has very limited chemotherapeutic options and
can synergize with almost all modalities of prevalent Pca therapy
Here is where we want to tell your story, how your work on Capridine flourished and why
you believe it development will help prostate cancer, and other cancer, patients. We call
this a “story-line mission statement”.
5. Prostate Cancer
The Second Leading Cause of Cancer Deaths in Men
5
The Facts.
Prostate cancer is the most common cancer in American men after skin
cancer.
In 2014
About 233,000 new cases of prostate cancer will be diagnosed
About 29,480 men will die of prostate cancer
About 1 man in 6 will be diagnosed with prostate cancer during his lifetime.
About 6 cases in 10 are diagnosed in men aged 65 or older, and it is rare
before age 40. The average age at the time of diagnosis is about 66.
Prostate cancer is the second leading cause of cancer death in American men,
after lung cancer. About 1 man in 36 will die of prostate cancer.
Prostate cancer can be a serious disease, but most men diagnosed with
prostate cancer do not die from it.
(Source: The American Cancer Society, Aug 2014)
$15B isspentonprostatecancerresearch
6. Chemotherapies’ Three Major Challenges in Treatment
6
Limited Efficacy for Metastatic Disease
Radiation, hormonal and chemotherapy remain palliative and
development of resistance very common
High Toxicity
Severe bone marrow toxicity and poor tolerance
Hormone Interdependence
PCa initiates as hormone sensitive and develops into hormone
refractory metastatic disease. Presently used chemodrugs are not
PCa associated
Effective drug-based therapy and immunotherapy is
an unmet clinical need in prostate cancer.
1.
2.
3.
7. 7
Clinical States and Stages in Prostate Cancer
Organ
Confined
Locally
Advanced
Disease
Rising PSA
Hormone Naive
Metastases
Castrate
Resistant
Asymptomatic
Metastases
Castrate
Resistant
Symptomatic
Metastases
Castrate
Resistant
Post Docetaxel
Post Abiranterone
Metastases
Castrate
Resistant
Post Cabazitaxel
STAGE 1 STAGE 2 STAGE 3 STAGE 4
Stage I: Surgery and Radiation or watchful waiting
Stage 2-4: Limited chemotherapy options, all drugs besides Taxotere and Cabizataxel are used as anti-
hormone. In Patients who are Resistant Only the 2 drugs above are used with significant toxicity.
Metastatic
Disease
(De Novo)
Rising PSA
Castrate
Model adapted from Dr. H, Scher, M.D.
8. 8
Current Drug Therapies in Use
During Critical States and Throughout Stages
Organ
Confined
Locally
Advanced
Disease
Rising PSA
Hormone Naive
Metastatic
Disease
(De Novo)
Rising PSA
Castrate
Metastases
Castrate
Resistant
Asymptomatic
Metastases
Castrate
Resistant
Symptomatic
Metastases
Castrate
Resistant
Post Docetaxel
Post Abiranterone
Metastases
Castrate
Resistant
Post Cabazitaxel
STAGE 1 STAGE 2 STAGE 3 STAGE 4
Denosumab
Zolendronic Acid
Abiraterone
Sipuleucel-T
Cabzitaxel
Denosumab
Zolendronic Acid
Abiraterone
Rad 233
Cabzitaxel
Rad233
Abiraterone
MDV-3100
MDV-3100
CAPRIDINE-β
Capridine-β can provide consistent treatment though Stages 2-4
Model adapted from Dr. H, Scher, M.D.
9. Capridine-β Advantages
9
NCI Tested, Prostate Cancer Specific
Over 7 million dollars invested in development (pre-
AVT)
Patent Protected
Capridine-beta and 200 of its derivatives are patent
protected for use as anticancer agents in US, EU,
Mexico, Canada, Israel
Limited Side Effects
Low blood and bone marrow toxicity. Does not kill
marrow or white blood cells
High therapeutic index for prostate
Low amount of drug, high efficacy. Wide, predicted
human therapeutic dose range
Active on hormone dependent and independent
prostate cancer
Xenograft studies suggest capridine is active against
hormone sensitive and refractory Pca.
Hormoen refractory cells are rendered sesnsitive suggesting a
combined use of Capridine and antihormone therapy
Capridine-β is active against taxane resistant prostate
cancer cell
Taxane resistant cells are sensitive to Capridine suggesting its
use in taxane resistant PCaMore text
Derivative R1 R2 R3 R4
C-1748 H (CH2)2OH CH3 H
1.
2.
3.
4.
5.
6.
10. Capridine-β and Hormone Independence
10
Typical Loss of Androgen Receptor
Early Step in Prostate Tumor Progression
Loss of
Androgen
Receptor
Upregulation
of ER-β
Upregulation
of CDC25
group
Capridine-β renders Hormone-Independent
DU-145 CaP Cells Hormone-Sensitive
6 hours 12 hours
C 5nM 10nM 5nM 10nM
Actin
Androgen receptor
0
0.5
1
1.5
Control 5nm (6hr) 10nm (6hr) 5nm (12hr) 10nm (12hr)
Induction of Androgen Receptor in DU-145 Cells
RelativeDensity
HormoneDependent
HormoneDependent
The progression of hormone sensitive to aggressive hormone
refractory metastatic
Pca reqiuires several cellular events Explanatory statement here:
11. Capridine-β Kills Prostate Cancer Preferentially
11
Prostate cancer cells (DU-145) are ten to 100 fold more sensitive to Capridine-β
than leukemic cells (HL-6O)
1 2
DU-145 Cells Treated with Capridine-β HL-60 Cells Treated with Capridine-β
12. Capridine-β Inhibits Hormone-Responsive and Non-
Responsive Xenografts in Nude Mice
12
1
3
2
4
Treatment Started Week 1, Administered Once Weekly for 7-9 Weeks
13. Comparative activity of Taxane and Capridine in Pca cells slide
13
Cell lines
IC50 Values (nM)
Taxane Capridine
LnCaP >100nM 15nM
PC3 16-20nM 5nM
DU145 15-20nM 5nM
LnCap a hormone dependent cell is resistant to taxane but sensitive to
Capridine. Both hormone dependent (LnCap) and refractory (PC-3
and DU145) are sensitive to Capridine .
14. Management Team
14
Abraham Mittelman , M.D.
Chief Executive Officer and Chairman of the Board
Oncologist and Associate Prof. at New York Medical
College (NYMC) with over 30 years of experience in
patient treatment and clinical trials.
Raj Tiwari, Ph.D.
Chief Scientific Officer
Professor of Microbiology & Immunology and Graduate
Program Director at NYMC with over 30 years of Cancer
Research, inventor of AVTs IPs related to Capridine and
Peptide Vaccine Technology.
Morton Coleman, M.D.,
Vice President, Director of Clinical Development
Clinical Professor at Weill Medical College, Cornell
University, Director of the Center for Lymphoma and
Myeloma at New York Presbyterian Hospital
Robert Pollock
President
Over 40 years business experience. Founder and
managing partner of Continuum Partners, a global network
security and business development consulting firm.
Jan Geliebter, Ph.D.
Secretary, VP Genomic Platforms
Professor of Microbiology & Immunology at NYMC with over
30 years of Cancer Research experience Holder of multiple
patents, including AVTs IP BCG-based prostate cancer
vaccine
Debabrata Banerjee, Ph.D.
VP Preclinical Development
Associate Professor of Medicine and Pharmacology,
Rutgers University with Over 30 years of experience in
preclinical and exptal therapeutics and Inventor of
several patents.
15. $3.0 Million Use of Proceeds
15
Objectives Capital Target Completion
2015 2016
Q1 Q2 Q3 Q4 Q1 Q2
Clinical Product Synthesis and Testing
1. GMP synthesis (complete)
2. Stability and toxicology $750,000
3. Formulation $250,000
IND Application & Phase 1 Approval
4. Contractual services for IND $200,000
5. Data analysis and compilation $100,000
6. Chemical manufacture write up $100,000
7. Comp lab mechanism studies $100,000
Phase 1
8. Multicenter Phase 1 $1,000,000
9.
10. Phase I/II Trials $500,000
Goal: Clinical development of Capridine-β in 2016 for licensing or commercialization.
16. Future Development Opportunities
16
Pros-Vax Peptide Therapeutic Vaccine
• Synthetic peptide vaccine (Pros-Vax) that mimics cancer proteins,
induces the host’s immune response directed against multiple cancer-
specific proteins
• Easily manufactured, small molecule drug
• Preclinical studies complete
• Expected to eliminate micrometasatic and residual disease and hence
prevent recurrence
Unimmunized rat Immunized rats
BTE6-LX-8b
ProVac 1
BTE6-X-15-7
ProVac 2
1.
0
10
20
30
40
50
60
Uterus Leukemia Breast Colon Lymphatic Sarcoma Prostate
Multiplesofeffectivenessof
CapridinecomparedtoMITX
Capridine
MITX
2. Capridine-β is also a Potent Anticancer
Drug in Several Cancers
• Capridine is highly effective for prostate cancers but can
also be used for other cancer therapies.
• Comparisons between the two drugs are based on IC50
values. IC50 is the drug concentration required to kill 50%
cells.
IC50 Value Results Demonstrated
Capridine is 3-55x More Effective on
Several Cancers
17. Why Invest in AVTH
17
Our preclinical studies are complete for Capridine. More than $6.0 million has
been invested in AV Therapeutics to date.
Our formulation of Capridine include no blood toxicity and wide therapeutic
dose range with specificity towards prostate cancer.
We are ready to commence phase I and II human trials.
Our team is comprised of internationally-recognized, well-published scientists,
clinicians (PhD’s and MDs) and medical research collaborators from leading
institutions
All of our IP is patent protected
1.
2.
3.
4.
5.
18. Contact Us
18
AV Therapeutics, Inc.
AdvancedCancerChemotherapies
Headquarters: 20 East 68th Street
Suite 204
New York , NY 10065
United States
EXECUTIVE:
Dr. Abraham Mittelman, M.D.
SCIENCE:
Dr. Raj Tiwari, Ph.D.
INVESTORS:
RedChip Companies, Inc.
Dave Gentry
Tel: 1-800-RED-CHIP (733-2447) x104
Email: info@redchip.com